{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-24-000088","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2024-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.919841+00:00","generated_at":"2026-05-31T04:28:20.315295+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ANI Pharma completes Alimera acquisition; expects high single-digit to low double-digit EPS accretion in 2025","bullets":["Acquired Alimera for $5.50/share plus CVR up to $0.50/share based on 2026-27 net revenue targets; repaid $72.5M Alimera debt.","Alimera adds ~$105M in pro forma 2024 revenue; Rare Disease segment to become ~45% of pro forma revenues.","New capital: $316.25M 2.25% convertible notes due 2029; new $325M term loan; interest expense reduced ~$39M annually.","Expects high single-digit to low double-digit accretion in 2025 adjusted non-GAAP EPS; substantially accretive thereafter; $35-38M adj. EBITDA.","Cortrophin Gel record new patient starts in Aug; ophthalmology team >3,600 physicians; 14 generic products launched YTD; maintains standalone 2024 guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-24-000088","json":"https://secwatch.observer/filing/0001023024-24-000088.json","markdown":"https://secwatch.observer/filing/0001023024-24-000088.md","text":"https://secwatch.observer/filing/0001023024-24-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000088/0001023024-24-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000088/ani-20240916.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:28:20.315295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}